RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Geni dell'angiogenesi indotti da ipossia: fattori di suscettibilità nella Sclerosi Laterale Amiotrofica ?
• 2 - CARATTERIZZAZIONE CLINICA, GENETICA ED EVOLUTIVA DEI FENOMENI EPILETTICI NEL SONNO E DEI DISTURBI DELL'AROUSAL
• 3 - Ruolo patogenetico del Brain-derived neurotrophic factor (BDNF) nell'eziologia delle patologie neurodegenerative: dai modelli animali allo studio nell'uomo.
• 4 - Iperinsulinismo congenito dell'infanzia: valutazione clinica e metabolica; analisi genetica e correlazione fenotipica; creazione registro nazionale.
• 5 - PEROSSIDAZIONE LIPIDICA, ATTIVAZIONE PIASTRINICA ED INFIAMMAZIONE ASSOCIATI A RIDOTTI LIVELLI DI LIPOPROTEINE AD ALTA DENSITA' (HDL)
• 6 - DISSEZIONE DEI FATTORI GENETICI E COMPRENSIONE DEI MECCANISMI RESPONSABILI DEL DIABETE AUTOIMMUNE
• 7 - Studio di biologia integrata ad alta produttività per l'analisi genetica della IgA nefropatia
• 8 - STUDI SUI FATTORI GENETICI ED IMMUNOLOGICI CHE REGOLANO IL DANNO TESSUTALE ED IL DECORSO CLINICO DELL'ARTRITE REUMATOIDE
• 9 - Ruolo delle adipochine, citochine infiammatorie e linfociti T regolatori nel determinismo dell’aterosclerosi accelerata e della sindrome metabolica in corso di lupus eritematoso sistemico.
• 10 - PRODUZIONE E CATABOLISMO DELLA BETA-AMILOIDE IN PAZIENTI CON MALATTIA DI ALZHEIMER E MILD COGNITIVE IMPAIRMENT: STUDI IN VITRO E MARKERS EX VIVO

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • GENETICA MEDICA
  • NEUROLOGIA
  • NEURORADIOLOGIA

Classificazione brevettuale

• HUMAN NECESSITIES
  • AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • DIAGNOSIS; SURGERY; IDENTIFICATION (analysing biological material G01N, e.g. G01N33/48; obtaining records using waves other than optical waves, in general G03B42/00)
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]

Classificazione geografica

• Regione: Calabria

Bibliografia

1.D ’Amelio M, Ragonese P, Morgante L, Tumor Diagnosis Preceding Parkinson’s Disease: A Case –Control Study. Mov Disord 2004;19:807-811.
2.Ragonese P, Salemi G, Morgante L, et al. A case control study on cigarette, alcohol, and coffee consumption preceding Parkinson’s disease. Neuroepidemiology 2003;22:297-304.
3.Ragonese P, D’Amelio M, Salemi G, et al. Risk of Parkinson disease in women Effect of reproductive characteristics. Neurology 2004;62:2010–2014.
4.Spillantini MG, Schimidt ML Lee VM, et al. Alpha-synuclein in Lewy Body. Nature 1997;388:839-840.
5.Leroy E, Boyer R, Auburger G, et al. The ubiquitin patway in Parkinson’s disease. Nature 1998:395:451-2.
6.Funayama M, Hasegawa K, Kowa H et al. A new locus for Parkinson’s disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 2002;51296-301.
7.Matsumine H, Saito M, Shimoda MS, et al. Localization of a genefro an autosomical recessive frorm of Juvenile Parkinsonism to chromosome 6q25.2-27 Am J Hum Genet 1997;60:588-96.
8.Van Duijin CM, Dekker MC, Bonifati V, et al. Park 7 a novel locus for autosomal recessive early onset parkinsonism, on chromosoma 1p36. AM J Hum Genet 2001;69:629-34.
9.Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early onset Parikinson’s disease caused by mutation of PINK1. Science 2004;3041120-2.
10.Nicoletti G, Annesi G, Tomaino C, et al. No evidence of association between the alpha-2 macroglobulin gene and Parkinson's disease in a case-control sample. Neurosci Lett. 2002;328:65-7.
11.Messina D, Annesi G, Serra P, et al. Association of the 5-HT6 receptor gene polymorphism C267T with Parkinson's disease. Neurology. 2002;58:828-9.
12.Zappia M, Annesi G, Quattrone A. Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD. Neurology. 2002;58:837.
13.Oliveri RL, Annesi G, Zappia M, et al. The dopamine D2 receptor gene is a susceptibility locus for Parkinson's disease. Mov Disord. 2000;15:127-31.
14.Tan EK, Khajavi M, Thornby JI, et al. Variability and validity of polymorphism association studies in Parkinson’s disease. Neurology 2000;55:533-538.
15.Bertram L and Tanìnzi R. The genetic epidemiology of neurodegenarative disease. The J Clin Invest 2005; 115:1449-1457.
16.Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and Multiple System Atrophy: a cross-sectional study. Lancet 1999, 354:1771-75.
17.Iwahashi K, Miyatake R, Tsuneoka Y, et al. A novel cytochrome P-450IID6 (CYPIID6) mutant gene associated with multiple system atrophy. J Neurol Neurosurg Psychiatry. 1995 Feb;58(2):263-4.
18.Nicholl DJ, Bennett P, Hiller L, et al. A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. European Study Group on Atypical Parkinsonism. Neurology. 1999 Oct 22;53(7):1415-21.
19.Infante J, Llorca J, Berciano J, et al. Interleukin-8, intercellular adhesion molecule-1 and tumour necrosis factor-alpha gene polymorphisms and the risk for multiple system atrophy. J Neurol Sci. 2005;228:11-3.
20.Combarros O, Infante J, Llorca J, et al.Interleukin-1A (-889) genetic polymorphism increases the risk of multiple system atrophy. Mov Disord. 2003;18:1385-6.
21.Bennett P, Bonifati V, Bonuccelli U, et al Direct genetic evidence for involvement of tau in progressive sopranuclear palsy. Neurology 1998; 51:982-985.
22.Colosimo C, Albanese A, Hughes AJ, et al. Some specific features differentiate MSA (striatonigral degeneration) from IPD. Archives of Neurology 1995;52:294-298.
23.Quinn N. Multiple System Atrophy: the nature of the beast. J Neurol Neurosug Psychiatry 1989 (Suppl): 78-89.
24.Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosi of multiple system atrophy. J Neurol Sci 1990; 163:94-98.
25.Schrag A, Good CD, Miszkiel K, Morris et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000;54:697-702.
26.Kraft E, Schwarz J, Trenkwalder C, et al. The combination of hypointense and hyperintense signal changes on T2-weighted magnetic resonance imaging sequences: a specific marker of multiple system atrophy? Arch Neurol 1999;56(2):225-228.
27.Schocke MF, Seppi K, Esterhammer R, et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology 2002;58:575-580.
28.Paviour DC, Price SL, Jahanshahi M, et al. Longitudinal MRI in PSP and MSA: rates and region of atrophy. Brain 2006; 129:1040-049.
29.Antonini A, Leenders KL, Vontobel P, et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson’s disease. Brain 1997;120:2187-2195.
30.Eckert T, Barnes A, Dhawan V, et al. FDG PET in the differential diagnosis of parkinsonian disorders. NeuroImage 2005, 26: 912-921.
31.Pellecchia MT, Pivonello R, Salvatore E, et al. Growth Hormone response to arginine test distinguishes Multiple system atrophy from Parkinson’s disease and Idiopathic late onset cerebellar ataxia. Clin Endocrinol (Oxf) 2005;62:428-33.
32.Bubendorf L. High-throughput microarray technologies: from genomics to clinics. Eur Urol 2001; 40:231-238.
33.Heller M.J. DNA MICROARRAY TECHNOLOGY: Devices, Systems, and Applications, Annu. Rev. Biomed. Eng 2002;4: 129-153.
34.Jaakson K. et al, Genotyping microarray (gene chip) for the ABCR (ABCA4) gene, Hum Mutat 2003;22:395-403.
35.Miyawaki E, Lyons K, Pahwa R, et al. Motor complications of chronic levodopa therapy in Parkinson's disease. Clin Neuropharmacol 1997; 20:523-530.
36.Gotham AM, Brown RG, Marsden CD. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain 1988; 111: 299-321.
37.Cools R, Barker RA, Sahakian BJ, et al. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex 2001; 11:1136-43.
38.Grandas F, Galiano ML, Tabernero C. Risk factors for levodopa-induced dyskinesia in Parkinson’s disease. J Neurol 1999; 246: 1127-1133.
39.Nutt JG, Holford NHG. The response to levodopa in Parkinson’s disease: imposing pharmacological law and order. Ann Neurol 1996; 39:561-573.
40.Kalow W. Pharmacogenetics in biological perspectives. Pharmacol Rev 1997; 49: 369-379.
41.Wang J, Liu ZL, Chen B. Association study of dopamine D2, D3 receptor gene polymorphism with motor fluctuations in PD. Neurology 2001; 56: 1757- 1759.
42.Oliveri RL, Annesi G, Zappia M, et al. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. Neurology 1999; 53: 1425-1430.
43.de la Fuente-Fernandez R, Nunez MA, Lopez E. The apolipoprotein E epsilon 4 allele increases the risk of drug-induced hallucinations in Parkinson's disease. Clin Neuropharmacol 1999; 22: 226-30.
44.Kaiser R, Hofer A Grapesgiesser A, Gasser et al. L-Dopa induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology 2003; 60: 1750-1755.
45.Goetz CG, Burke PF, Leurgans S, Berry, et al. Genetic variation analysis in Parkinson’s disease patients with and without hallucinations: case-control study. Arch Neurol 2001; 58: 209-213.
46.Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease Neurosci Biobehav Rev. 2006; 30: 1-23. Review.
47.Meyer-Lindenberg A, Kohn PD, Kolachana B, et al. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat Neurosci 2005; 8: 594-596.
48.Mattay VS, Goldberg TE, Fera F, et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A 2003;100: 6186-91.

Parole Chiave

MALATTIA DI PARKINSON, PARKINSONISMI, FARMACOGENETICA, NEUROIMAGING, DISCINESIE, RECETTORI DOPAMINERGICI